 | Up a level |
Journal Article
Loibl, Sibylle, Untch, Michael, Burchardi, Nicole, Huober, Jens Bodo, Blohmer, Jens U., Grischke, Eva-Maria, Furlanetto, Jenny, Tesch, Hans, Hanusch, Claus, Rezai, Mahdi, Jackisch, Christian, Schmitt, Wolfgang D., Von Minckwitz, Gunter, Thomalla, Jorg, Kummel, Sherko, Rautenberg, Beate, Fasching, Peter A., Rhiem, Kerstin, Denkert, Carsten and Schneeweiss, Andreas (2018). Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Von Minckwitz, Gunter, Hahnen, Eric, Fasching, Peter A., Hauke, Jan, Schneeweiss, Andreas, Salat, Christoph, Rezai, Mandi, Blohmer, Jens U., Zahm, Dirk Michael, Jackisch, Christian, Gerber, Bernd, Klare, Peter, Kummel, Sherko, Eidtmann, Holger, Paepke, Stefan, Nekljudova, Valentina, Le Loibl, Sibyl, Untch, Michael and Schmutzler, Rita K. (2014). Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755